RESUMEN
BACKGROUND AND OBJECTIVES: A new chromatographic step for the selective binding of abnormal prion protein (PrP(Sc)) was developed, and optimization for PrP(Sc) capture was achieved by binding to an affinity ligand attached to synthetic resin particles. This step was implemented into the manufacturing process of the solvent/detergent (S/D)-treated biopharmaceutical quality plasma Octaplas to further improve the safety margin in terms of risk for variant Creutzfeldt-Jakob disease (vCJD) transmission. MATERIALS AND METHODS: Intermediates and Octaplas final container material, spiked with hamster brain-derived PrP(Sc)-containing fractions, were used for experiments to establish the feasibility of introducing this novel chromatography step. The binding capacity per millilitre of ligand gel was determined under the selected manufacturing conditions. In addition, the specificity of the ligand gel to bind PrP(Sc) from human sources was investigated. A validated Western blot test was used for the identification and quantification of PrP(Sc). RESULTS: A reduction factor of > or = 3.0 log(10) could be demonstrated by Western blotting, utilizing the relevant Octaplas matrix from manufacturing. In this particular cell-free plasma solution, the PrP(Sc) binding capacity of the selected gel was very high (> or = 6 log(10) ID(50)/ml, equivalent to roughly 10 log(10) ID(50)/column at manufacturing scale). The gel binds specifically PrP(Sc) from both animal (hamster and mouse) and human (sporadic and variant CJD) sources. CONCLUSION: This new single-use, disposable PrP(Sc)-harvesting gel ensures a very high capacity in terms of removing the pathogenic agent causing vCJD from the new generation OctaplasLG, in the event that prions can be found in plasma from donors incubating the disease and thereby contaminating the raw material plasma used for manufacturing.
Asunto(s)
Patógenos Transmitidos por la Sangre/aislamiento & purificación , Cromatografía de Afinidad/métodos , Detergentes/farmacología , Plasma/efectos de los fármacos , Proteínas PrPSc/aislamiento & purificación , Resinas Sintéticas/farmacología , Solventes/farmacología , Desintoxicación por Sorción/métodos , Animales , Western Blotting , Síndrome de Creutzfeldt-Jakob/prevención & control , Cricetinae , Estudios de Factibilidad , Enfermedad de Gerstmann-Straussler-Scheinker , Humanos , Mesocricetus , Ratones , Proyectos Piloto , Proteínas PrPSc/análisis , Unión Proteica , Reproducibilidad de los Resultados , Scrapie , Factores de TiempoRESUMEN
BACKGROUND AND OBJECTIVES: A new chromatographic step for the selective binding of pathological prion proteins (PrP(Sc)) to an affinity ligand, developed and optimized for PrP(Sc) capture and attached to synthetic resin particles (PRDT, USA; ProMetic BioSciences Ltd, Isle of Man, UK) was implemented into the manufacturing process of the solvent/detergent (S/D) treated biopharmaceutical quality plasma Octaplas. MATERIALS AND METHODS: Pilot batches of Octaplas with the implemented chromatographic step [labelled as OctaplasLG (ligand gel)] were manufactured by Octapharma PPGmbH, Vienna, Austria. The biochemical quality was compared directly after manufacturing as well as after 18 months storage. All samples were tested on global coagulation parameters, fibrinogen levels, activities of coagulation factors and protease inhibitors, ADAMTS13 levels, as well as markers of activated coagulation and fibrinolysis. In addition, von Willebrand factor multimeric analysis was performed. RESULTS: The incorporation of this novel chromatography into the large-scale routine manufacturing process was shown to be technically feasible and the performance of the column was assessed to be excellent. The biochemical studies showed that Octaplas and OctaplasLG produced without and with the new column, respectively, demonstrate an identical biochemical quality. OctaplasLG remained stable over a period of 18 months stored frozen. A parallel reduction of the S/D virus inactivation step from 4-4.5 to 1-1.5 h led to significantly higher activities of plasmin inhibitor. CONCLUSION: The studies confirmed that the affinity ligand chromatography under the developed conditions can be introduced into the Octaplas manufacturing process, as a mean to reduce potentially present PrP(Sc), without hampering the proven quality of this product.
Asunto(s)
Patógenos Transmitidos por la Sangre/aislamiento & purificación , Cromatografía de Afinidad/métodos , Detergentes/farmacología , Plasma/efectos de los fármacos , Proteínas PrPSc/aislamiento & purificación , Resinas Sintéticas/farmacología , Solventes/farmacología , Desintoxicación por Sorción/métodos , Proteínas ADAM/sangre , Proteína ADAMTS13 , Pruebas de Coagulación Sanguínea , Conservación de la Sangre , Estudios de Factibilidad , Fibrinógeno/análisis , Humanos , Proyectos Piloto , Unión Proteica , Tromboelastografía , Trombina/biosíntesis , Factores de Tiempo , Factor de von Willebrand/análisis , Factor de von Willebrand/químicaRESUMEN
Aqueous polymer two-phase systems containing dextran T-500 and PEG 4000 can be prepared which are biphasic below 18 degrees C and monophasic at higher temperatures. Both liganded and unliganded forms of glutamate dehydrogenase and troponin, which have similar partition coefficients if the protein is added to a two-phase system at 4 degrees C, have widely differing partition coefficients if added to the same system in the monophasic state at 20 degrees C and subsequently cooled to 4 degrees C.